Evolus, Inc. (NASDAQ:EOLS) Shares Purchased by Nantahala Capital Management LLC

Nantahala Capital Management LLC boosted its position in shares of Evolus, Inc. (NASDAQ:EOLS - Free Report) by 10.8% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,130,149 shares of the company's stock after buying an additional 305,300 shares during the period. Evolus accounts for about 1.5% of Nantahala Capital Management LLC's portfolio, making the stock its 9th largest holding. Nantahala Capital Management LLC owned 4.94% of Evolus worth $34,557,000 at the end of the most recent reporting period.

A number of other hedge funds have also made changes to their positions in EOLS. Northern Trust Corp increased its position in shares of Evolus by 9.3% during the fourth quarter. Northern Trust Corp now owns 531,167 shares of the company's stock worth $5,864,000 after purchasing an additional 45,384 shares in the last quarter. Tri Locum Partners LP purchased a new stake in shares of Evolus during the fourth quarter worth $8,198,000. Boothbay Fund Management LLC raised its position in shares of Evolus by 30.9% in the fourth quarter. Boothbay Fund Management LLC now owns 1,287,767 shares of the company's stock valued at $14,217,000 after buying an additional 304,065 shares during the last quarter. Gilder Gagnon Howe & Co. LLC lifted its stake in shares of Evolus by 287.2% in the fourth quarter. Gilder Gagnon Howe & Co. LLC now owns 702,239 shares of the company's stock worth $7,753,000 after buying an additional 520,859 shares in the last quarter. Finally, Oberweis Asset Management Inc. lifted its stake in shares of Evolus by 31.6% in the fourth quarter. Oberweis Asset Management Inc. now owns 677,600 shares of the company's stock worth $7,481,000 after buying an additional 162,700 shares in the last quarter. Institutional investors and hedge funds own 90.69% of the company's stock.

Insider Activity

In other Evolus news, insider Rui Avelar sold 27,904 shares of the company's stock in a transaction on Tuesday, March 18th. The stock was sold at an average price of $13.26, for a total transaction of $370,007.04. Following the transaction, the insider now directly owns 362,467 shares in the company, valued at $4,806,312.42. This represents a 7.15 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Karah Herdman Parschauer sold 12,888 shares of Evolus stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $12.99, for a total value of $167,415.12. Following the completion of the sale, the director now directly owns 32,183 shares of the company's stock, valued at $418,057.17. The trade was a 28.59 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 60,575 shares of company stock valued at $794,369 in the last quarter. Insiders own 6.10% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on EOLS. HC Wainwright reissued a "buy" rating and issued a $27.00 target price on shares of Evolus in a research note on Thursday, April 10th. Needham & Company LLC reaffirmed a "buy" rating and issued a $22.00 price target on shares of Evolus in a report on Wednesday, April 9th. Barclays upped their target price on Evolus from $22.00 to $25.00 and gave the company an "overweight" rating in a report on Wednesday, March 5th. Finally, BTIG Research started coverage on Evolus in a report on Thursday, April 17th. They set a "buy" rating and a $21.00 price target on the stock. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat, Evolus has a consensus rating of "Buy" and an average target price of $23.75.

Evolus Trading Up 2.4 %

EOLS traded up $0.28 during trading hours on Friday, reaching $12.08. The company's stock had a trading volume of 957,476 shares, compared to its average volume of 666,727. The business's 50-day moving average is $11.98 and its 200-day moving average is $12.77. The company has a debt-to-equity ratio of 20.58, a current ratio of 2.47 and a quick ratio of 2.23. The stock has a market cap of $778.81 million, a PE ratio of -13.27 and a beta of 1.11. Evolus, Inc. has a fifty-two week low of $8.67 and a fifty-two week high of $17.82.

Evolus Company Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.